Leishmaniasis drug candidate tested in healthy volunteers
NCT ID NCT04504435
First seen May 10, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study was the first to give GSK3494245 to humans, testing its safety and how the body processes it. It involved 59 healthy adults who received up to three doses of the drug or a placebo. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
Conditions
Explore the condition pages connected to this study.